Advertisement

Parkinson’s disease and PET tracer studies

  • K. L. Leenders
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)

Summary

Although the cause of Parkinson’s disease is still unknown it has become clear that dopaminergic cell loss in the substantia nigra is a prominent feature of the disease. The study of cerebral dopaminergic function — dominated by the nigrostriatal system —in relation to motor abnormalities and their response to treatment has been in the centre of research for many years. However, until recently it was not possible to approach metabolism or neurotransmitter function in brain directly in vivo. To be able to do so seems highly necessary since Parkinson’s disease is a slowly progressive condition and one wishes to know how cerebral functions are deranged in the beginning of the disease.

Positron emission tomography (PET) using specific tracers (labelled with short-lived radionuclides like oxygen-15, carbon-11 or fluorine-18) can measure certain physiological or biochemical functions focally in brain directly in patients or healthy volunteers (for an extensive overview, see Phelps, 1986).

Keywords

Positron Emission Tomography Parkinsonian Patient Positron Emission Tomography Tracer Dopaminergic Cell Loss Living Human Brain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aquilonius S, Bergstrom K, Eckernas S etal (1987) In vivo evaluation of striatal dopamine re-uptake sites using C-Nomifensine and positron emission tomography. Acta Neurol Scand 76: 283–287PubMedCrossRefGoogle Scholar
  2. Bokobza B, Ruberg M, Scatton B etal (1984) (3H)spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175Google Scholar
  3. Calne DB, Langston JW, Martin WRW etal (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 317: 246–248PubMedCrossRefGoogle Scholar
  4. Farde L, Hall H, Ehrin E, Sedval G (1986) Quantitative analysis of dopamine-D-2 receptor binding in the living human brain using positron emission tomography. Science 231: 258–261PubMedCrossRefGoogle Scholar
  5. Fowler J, MacGregor R, Wolf A etal (1987) Regional distribution of monoamine oxidase A and B in human brain using 1-suicide inhibitors and positron emission tomography. Science 235: 481–485PubMedCrossRefGoogle Scholar
  6. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305: 137–138PubMedCrossRefGoogle Scholar
  7. Kilbourn MR, Zalutski MR (1985) Research and clinical potential of receptor based radiopharmaceuticals. J Nucl Med 26: 655–662PubMedGoogle Scholar
  8. Leenders KL, Wolfson L, Gibbs JM, Wise RJS, Causon R, Jones T, Legg NJ (1985 a) The effects of L-dopa on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. Brain 108: 171–191Google Scholar
  9. Leenders KL, Herold S, Palmer A (1985 b) Human cerebral dopamine system measured in vivo using PET. J Cereb Blood Flow Metab 5 [Suppl]: 517–518Google Scholar
  10. Leenders KL, Palmer AJ, Quinn N etal (1986a) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–856PubMedCrossRefPubMedCentralGoogle Scholar
  11. Leenders KL, Palmer A, Turton D et al ( 1986 b) Recent developments in Parkinson’s disease. Raven Press, New York, pp 103–113Google Scholar
  12. Leenders KL, Poewe WH, Palmer A etal (1986c) Inhibition of L-dopa uptake into the human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258–262PubMedCrossRefGoogle Scholar
  13. Leenders KL, Aquilonius S, Bergstrom etal (1987) Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res (in press) Nahmias C, Garnett ES, Firnau G, Lang A (1985) Striatal dopamine distribution in Parkinsonian patients during life. J Neurol Sci 69: 223–230Google Scholar
  14. Phelps ME, Mazziotta JC, Schelbert HR (eds) Positron emission tomography and autoradiography. Principles and applications for the brain and heart. Raven Press, New YorkGoogle Scholar
  15. Wagner HN, Burns HD, Dannals RF et al (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 1264–1266PubMedCrossRefGoogle Scholar
  16. Wolfson L, Leenders KL, Brown L, Jones T (1985) Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson’s disease. Neurology 35: 1399–1405PubMedCrossRefGoogle Scholar
  17. Wong DF, Wagner HN, Dannals RF et al (1984) Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226: 1393–1396PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • K. L. Leenders
    • 1
  1. 1.MRC Cyclotron UnitHammersmith HospitalLondonUK

Personalised recommendations